Now Accepting Nominations for Preclinical Testing
Nominations accepted until Friday, June 10, 2022
Interested principal investigators (PI) are invited to nominate candidate therapeutics for testing in the TSC Preclinical Consortium’s tumor models. Please complete the short nomination form, available on the TSC Alliance Preclinical Consortium webpage. The form requests no more than two pages of text and/or figures to describe the rationale for the compound and its mechanism of action for TSC. The lead PI must also submit an NIH-style biosketch.
Nominations will be accepted until Monday, August 1, 2022.
Companies interested in nominating compounds and retaining confidentiality and ownership of the data should not utilize the nomination form and should contact Dean Aguiar, PhD, Vice President, Translational Research, directly (email@example.com).